Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Ursodeoxycholic Acid is an important clinical drug in the treatment of gallstones, cholecystitis, PBC, and PSC and has broad market prospects. In previous work, ursodeoxycholic acid was prepared by traditional organic synthesis.
Scope of the Report:
The classification of Ursodeoxycholic Acid Drug Product includes Capsule and Tablet. And the proportion of Capsule in 2017 is about 94.8%, and the proportion is in decreasing trend from 2013 to 2018, In China, the major product is tablet, and with low concentration UDCA, and the price is also low than other manufacturers. The major products of Dr. Falk Pharma, Daewoong Pharmaceutical, Teva are capsule.
Ursodeoxycholic Acid Drug Product can be applied in Gallstone, Hepatopathy, Biliary Disease and Other. The most of Ursodeoxycholic Acid Drug Product is used in Gallstone, and the market share of that is about 36.5% in 2017.
North America is the largest sales place, with a sales market share nearly 30% in 2017. Following North America, Europe is the second largest sales place with the Sales market share of 22.1%. Ursodeoxycholic Acid Drug Product market in Asia Pacific region is expected to exhibit the highest growth rate especially in the developing Asian countries like China & India.
Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, etc. are the global leading manufactures in the world. In the future, more generic manufacturers will enter into this industry.
In North America, Epic Pharma is leading manufacturers, Teva, Lannett and Mylan are major suppliers of Ursodeoxycholic Acid Drug Product in USA market. In China, Dr. Falk Pharma is leading manufacturers, the market share is about 81% in 2017. In Japan, Mitsubishi Tanabe Pharma is leading manufacturers, the market share is about 52% in 2017. In Korea, Daewoong Pharmaceutical is leading manufacturers, the market share is about 86.1% in 2017
The worldwide market for Ursodeoxycholic Acid Drug Product is expected to grow at a CAGR of roughly 11.9% over the next five years, will reach 1900 million US$ in 2024, from 970 million US$ in 2019, according to a new study.
This report focuses on the Ursodeoxycholic Acid Drug Product in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Capsule
Tablet
Market Segment by Applications, can be divided into
Gallstone
Hepatopathy
Biliary Disease
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Ursodeoxycholic Acid Drug Product product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Ursodeoxycholic Acid Drug Product, with price, sales, revenue and global market share of Ursodeoxycholic Acid Drug Product in 2017 and 2018.
Chapter 3, the Ursodeoxycholic Acid Drug Product competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Ursodeoxycholic Acid Drug Product breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Ursodeoxycholic Acid Drug Product market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Ursodeoxycholic Acid Drug Product sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Scope of the Report:
The classification of Ursodeoxycholic Acid Drug Product includes Capsule and Tablet. And the proportion of Capsule in 2017 is about 94.8%, and the proportion is in decreasing trend from 2013 to 2018, In China, the major product is tablet, and with low concentration UDCA, and the price is also low than other manufacturers. The major products of Dr. Falk Pharma, Daewoong Pharmaceutical, Teva are capsule.
Ursodeoxycholic Acid Drug Product can be applied in Gallstone, Hepatopathy, Biliary Disease and Other. The most of Ursodeoxycholic Acid Drug Product is used in Gallstone, and the market share of that is about 36.5% in 2017.
North America is the largest sales place, with a sales market share nearly 30% in 2017. Following North America, Europe is the second largest sales place with the Sales market share of 22.1%. Ursodeoxycholic Acid Drug Product market in Asia Pacific region is expected to exhibit the highest growth rate especially in the developing Asian countries like China & India.
Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, etc. are the global leading manufactures in the world. In the future, more generic manufacturers will enter into this industry.
In North America, Epic Pharma is leading manufacturers, Teva, Lannett and Mylan are major suppliers of Ursodeoxycholic Acid Drug Product in USA market. In China, Dr. Falk Pharma is leading manufacturers, the market share is about 81% in 2017. In Japan, Mitsubishi Tanabe Pharma is leading manufacturers, the market share is about 52% in 2017. In Korea, Daewoong Pharmaceutical is leading manufacturers, the market share is about 86.1% in 2017
The worldwide market for Ursodeoxycholic Acid Drug Product is expected to grow at a CAGR of roughly 11.9% over the next five years, will reach 1900 million US$ in 2024, from 970 million US$ in 2019, according to a new study.
This report focuses on the Ursodeoxycholic Acid Drug Product in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Capsule
Tablet
Market Segment by Applications, can be divided into
Gallstone
Hepatopathy
Biliary Disease
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Ursodeoxycholic Acid Drug Product product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Ursodeoxycholic Acid Drug Product, with price, sales, revenue and global market share of Ursodeoxycholic Acid Drug Product in 2017 and 2018.
Chapter 3, the Ursodeoxycholic Acid Drug Product competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Ursodeoxycholic Acid Drug Product breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Ursodeoxycholic Acid Drug Product market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Ursodeoxycholic Acid Drug Product sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
